BRAF and cancer: The different cancer histology was associated with a marked reduction of cell proliferation of BRAF FOXE1+/− cancers, as determined by immunohistochemistry (IHC) for Ki-67, compared to BRAF FOXE1+/+ (Figure 3A,B).